Program
(click here to download a pdf version)

“New developments in Multiple Myeloma”
Chairmen: Jesus San Miguel and Jean-Luc Harousseau

FRIDAY, MAY 15, 2009

Registration opens at 10:00 am. Lunch buffet available from 12:00

13.00 – 13.05

Welcome & Opening words
J. San Miguel,
 J.L. Harousseau,  M. Aapro

13.05 – 13.30

Keynote lecture
R. Kyle

 

 

SESSION I: Biology and prognostic Indicators
Chair: M. Aapro

Each 12 minute presentation is preceded and followed by one interactive question using a keypad followed by 8 minutes discussion

13.30 – 13.50

Phenotype of the myeloma cell. Clinical implications.
J. San Miguel

13.50 – 14.10

Signal transduction and apoptosis.
C. Pellat

14.10 – 14.30

The use of cytogenetics for defining prognosis and tailoring treatment
J. Drach

 

SESSION II: The role of novel agents in front-line therapy in elderly patients
Chair: J. San Miguel

Each 12 minute presentation is preceded and followed by one interactive question using a keypad followed by 8 minutes discussion

14.30 – 14.50 

Thalidomide
C. Hulin

14.50 – 15.10

Bortezomib
M.V. Mateos

15.10 – 15.30

Lenalidomide
M. Boccadoro

15.30 – 15.50

Is there a role for autologous stem-cell transplantation?
H. Einsele

15.50 – 16.10

Panel discussion: Optimal treatment of elderly patients: questions to be adressed in randomised trials.
J. San Miguel, M.V. Mateos, M. Boccadoro, H. Einsele

16.10 – 16.30

Coffee Break

 

 

SESSION III: Fighting the disease: maximizing benefits while minimizing side-effects
Chair: H. Ludwig

12 minute presentations are preceded and followed by interactive questions using a keypad and followed by 8 minute discussion

16.30 – 16.50

Renal Failure
H. Ludwig

16.50 – 17.10

The bone and the expert: what is the 2009 consensus?
E. Terpos

17.10  – 17.30

Side effects of new therapies: how to prevent and handle
A. Palumbo

17.30                      

Closure of the day.

20.00                 

Depart from the hotel lobby to Course Dinner.

 

 

SATURDAY MAY 16, 2008

SESSION IV: The role of novel agents in the context of transplantation
Chair: JL Harousseau

12 minute presentations are preceded and followed by interactive questions using a keypad followed by a 5 minute group discussion

08.30 – 08.50

Induction treatment prior to autologous stem cell transplantation
M. Cavo

08.50 – 09.10

Novel agents given before and after autogolous stem cell transplantation
M. Attal

09.10 – 09.30

The role of novel agents in allogeneic stem-cell transplantation
N. Kröger

09.30 – 09.50

Panel Discussion: Optimal treatment of younger patients: questions to be addressed in randomized trials
J.L. Harousseau, M. Cavo, M Attal, P. Sonneveld,  N. Kröger

09.50 – 10.10

Coffee Break

 

SESSION V: Treatment of relapsed disease
Chair: P. Sonneveld

Each 12 minute presentation is preceded and followed by one interactive question using a keypad followed by 8 minutes discussion

10.10 – 10.30

How to design and interpret clinical trials in relapsed Multiple Myeloma: definition of the population and of the objectives
M. Delforge

10.30 – 10.50

Novel agents in evaluation
E. Ocio

10.50 – 11.10

Panel discussion: Current strategies in relapsed Multiple Myeloma
All speakers

 

SESSION VI: Current algorithms and future perspectives
Chair: J. San Miguel

Each 12 minute presentation is preceded and followed by one interactive question using a keypad followed by 8 minutes discussion

11.10 – 11.30

The use of new genetic tools for prognostication in Multiple Myeloma -introduction on risk-adapted strategy
H. Avet-Loiseau

11.30 – 11.50

Should complete remission be the primary objective of therapy?
J.L. Harousseau

11.50 – 12.10

The role of continuous therapy: searching for the cure or changing Multiple Myeloma  into a chronic disease.
P. Sonneveld

12.10 – 12.20

Learning Assessments: Attendees to fill in their evaluation forms and answer 15 questions based on the course. Certificates will be given ONLY afterwards

12.20 – 14.00

Lunch-buffet and certificate delivery